1. Home
  2. Staff
  3. University Academic Staff
  4. Prof LUI Tak Wai David Profile

Professor LUI Tak Wai, David

Prof David Lui

Clinical Assistant Professor

  • MBBS (Hons) (HK); MRCP (UK); FHKCP; FHKAM (Medicine)
email dtwlui@hku.hk
email 2255-4704
email HKU Scholars Hub
Personal Page: https://orcid.org/0000-0002-9813-1126
Citation Report: https://www.webofscience.com/wos/author/record/2101206
Biography
Prof David Lui obtained his MBBS degree with Honours from the University of Hong Kong and completed his specialty training in Endocrinology, Diabetes, and Metabolism at Queen Mary Hospital. He joined the Department of Medicine at the University of Hong Kong as a Clinical Assistant Professor in March 2021.

His research interests include bone and muscle health in diabetes, lipid disorders and cardiovascular risks in diabetes, parathyroid and adrenal disorders. Supported by the Health and Medical Research Fund, he is leading a randomized controlled trial on the effects of statins on bone health in postmenopausal women with type 2 diabetes, studying the epidemiology of fractures in type 2 diabetes within Hong Kong, and examining the long-term impacts of COVID-19 on metabolic disorders. Prof Lui has established cohorts to evaluate osteoporosis and sarcopenia in individuals with and without diabetes and has contributed to the development of the 2024 OSHK Guideline for the Clinical Management of Postmenopausal Osteoporosis in Hong Kong, particularly the section on ‘Diabetes and Osteoporosis’. Additionally, he was a visiting fellow at the University of New South Wales, Sydney, during 2024/25, where he studied high-density lipoprotein function in type 2 diabetes under the mentorship of Professor Kerry Rye. 

He has authored over 110 peer-reviewed articles in international journals, including Nature Reviews Endocrinology, Diabetes Care, EClinicalMedicine, JAMA Surgery, and JAMA Network Open. Two of his publications have been listed among the Highly Cited Papers in the Essential Science Indicators (ESI). In recognition of his research contributions, he has received numerous awards, including the Distinguished Research Paper Award for Young Investigators from the Hong Kong College of Physicians (2021, 2022, and 2023) and the Rising Star Award at the International Congress of Diabetes and Metabolism (2021). He currently serves on the Editorial Board of Endocrine Practice. He is an active member of the Asia-Pacific Consortium on Osteoporosis (APCO) and the Asia-Pacific Cardio-Metabolic Consortium (APCMC).


Research Profile
  • Osteoporosis and sarcopenia in diabetes
  • Lipid disorders and cardiovascular risks in diabetes
  • Primary hyperparathyroidism: epidemiology and role of parathyroidectomy
  • Adrenal incidentaloma
  • COVID-19 and endocrinology

Selected publications
Total of 114 publications (link to more publications: https://pubmed.ncbi.nlm.nih.gov/?term=lui+dtw)
  1. Lui DTW, Lee CH, Woo YC, Hung IFN, Lam KSL. Thyroid dysfunction in COVID-19. Nat Rev Endocrinol. 2024;20(6):336-348. https://doi.org/10.1038/s41574-023-00946-w (2024 JIF 42.3)
  2. Lui DTW, Tang EHM, Au ICH, Wu T, Lee CH, Wong CK, Cheung CYY, Fong CHY, Chow WS, Woo YC, Tan KCB, Lam KSL, Wong CKH. Evaluation of fracture risk among patients with type 2 diabetes and non-valvular atrial fibrillation receiving different oral anticoagulants. Diabetes Care. 2022;45(11):2620-2627. https://doi.org/10.2337/dc22-0664 (2024 JIF: 16.6)
  3. Lui DTW, Cheung CL, Lee ACH, Wong Y, Shiu SWM, Tan KCB. Carbamylated HDL and mortality outcomes in type 2 diabetes. Diabetes Care. 2021;44(3):804-809. https://doi.org/10.2337/dc20-2186 (2024 JIF: 16.6)
  4. Liu X*, Lui DTW*,#, Xiong X, Li L, Luk Y, Wong CH, Lee CH, Wong CKH, Fung MMH, Lang BHH#. Parathyroidectomy is associated with lower risk of incident diabetes among patients with primary hyperparathyroidism. JAMA Surg. 2025;160(10):1125-1132. https://doi.org/10.1001/jamasurg.2025.3081 (2024 JIF: 14.9; *co-first and #co-corresponding author) (Editorial Comments: https://doi.org/10.1001/jamasurg.2025.3075)
  5. Lui DTW, Tang EHM, Wu T, Au ICH, Lee CH, Woo YC, Tan KCB, Wong CKH. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based study in Hong Kong. Cardiovasc Diabetol. 2023;22(1):40. https://doi.org/10.1186/s12933-023-01772-0 (2024 JIF: 10.6)
  6. Wong CKH, Lau KTK, Tang EHM, Lee CH, Lee CYY, Woo YC, Tan KCB, Lui DTW. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study. Cardiovasc Diabetol. 2022;21(1):92. https://doi.org/10.1186/s12933-022-01520-w (2024 JIF: 10.6; corresponding author)
  7. Lui DTW, Au ICH, Tang EHM, Cheung CL, Lee CH, Woo YC, Wu T, Tan KCB, Wong CKH. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: a real-world population-based analysis.  EClinicalMedicine. 2022;50:101510. https://doi.org/10.1016/j.eclinm.2022.101510  (2024 JIF: 10.0)
  8. Xiong X*, Lui DTW*, Chung MSH, Au ICH, Lai FTT, Wan EYF, Chui CSL, Li X, Cheng FWT, Cheung CL, Chan EWY, Lee CH, Woo YC, Tan KCB, Wong CKH, Wong ICK. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: a population-based cohort study. PLoS Med. 2023;20(7):e1004274. https://doi.org/10.1371/journal.pmed.1004274 (2024 JIF 9.9; *co-first author)
  9. Lui DTW, Chung MSH, Lau EHY, Lau KTK, Au ICH, Lee CH, Woo YC, Wong CKH, Cowling BJ. Analysis of all-cause hospitalization and death among non-hospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir and nirmatrelvir-ritonavir during the Omicron wave in Hong Kong. JAMA Netw Open. 2023;6(5):e2314393. doi:10.1001/jamanetworkopen.2023.14393 (2024 JIF 9.7)
  10. Xiong X*, Lui DTW*,#, Ju C, Chandran M, Wong CKH#. Associations of albuminuria and metabolic syndrome traits with fracture risk in type 2 diabetes: a population-based cohort study. J Cachexia Sarcopenia Muscle. 2026. (in press) (2024 JIF: 9.1; *co-first and #co-corresponding author)

Awards
  • Prize for Best Original Research by Young Fellows, Bronze Medal, Hong Kong Academy of Medicine (2025)
  • Best Oral Presentation Award, International Congress of Diabetes and Metabolism (2025)
  • Excellent Oral Presentation, Seoul International Congress of Endocrinology and Metabolism (2025)
  • Travel Grant Award (Outstanding Class), International Congress of Diabetes and Metabolism (2024)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2023)
  • Merit Abstract Award in Clinical Research, 28th Medical Research Conference (2023)
  • Li Ka Shing Medical Fellowship for Internal Medicine (2023)
  • Faculty Outstanding Research Output Award, HKUMed (2022)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2022) (with Best Presenter Award)
  • ISE Abstract Award, 20th International Congress of Endocrinology (2022)
  • Endocrine Society Outstanding Abstract Award, ENDO 2022 (2022)
  • Best Abstract in Clinical Medicine (Poster), 27th Medical Research Conference (2022)
  • Best Poster Exhibition Award in 9th Seoul International Congress of Endocrinology and Metabolism (2021)
  • Rising Star Award, International Congress of Diabetes and Metabolism (2021)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2021)
  • Best Abstract in Clinical Medicine (Oral), 26th Medical Research Conference (2021)
  • International Non-Fellow Physician AACE Travel Grant Award, AACE 29th Annual Scientific & Clinical Congress (2020)
  • Poster Award, Asia Islet Biology & Incretin Symposium (2019)
  • Best Abstract in Clinical Medicine (Poster), 24th Medical Research Conference (2019)

Grant Record
External competitive grants as Principal Investigator
  • Health and Medical Research Fund 2022 – Risks and burdens of metabolic sequelae in long COVID: focusing on glucose, lipid and bone metabolism (Ref: 21222081; HKD 1,493,807)
  • Health and Medical Research Fund 2021 – Fragility fractures in type 2 diabetes as an emerging diabetic complication: epidemiology, burden and strategies of primary prevention (Ref: 20211971; HKD 678,248)
  • Health and Medical Research Fund 2020 – The effect of simvastatin on bone density in postmenopausal women with type 2 diabetes: a double-blind, randomized, active-comparator (ezetimibe) controlled clinical trial (Ref: 19200931; HKD 1,478,393)



Key Office
  • Secretary, Diabetes Division of Hong Kong Society of Endocrinology, Metabolism and Reproduction (2025 – now)
  • Executive Committee Member, Asia Pacific Consortium on Osteoporosis (2025 – now)
  • Communications Workgroup Co-Lead, Asia Pacific Cardiometabolic Consortium (2025 – now)
  • Young Fellow, Specialty Board of Endocrinology, Diabetes and Metabolism, Hong Kong College of Physician (2025 – now)
  • Member, Editorial Board, AACE Endocrinology and Diabetes (2025 – now)
  • Member, Editorial Board, The Journal of Clinical Endocrinology and Metabolism (2024 – 2025)
  • Member, Editorial Board, Endocrine Practice (2024 – now)
  • Director, Osteoporosis Centre, The University of Hong Kong (2024 – now)